Two different levers on the same gland
Growth hormone is not released continuously. The pituitary puts it out in pulses, and how big those pulses are is governed by a push-and-pull between three signals: growth-hormone-releasing hormone (GHRH) pushing release up, ghrelin amplifying it, and somatostatin holding it back. Any compound described as a "GH peptide" is acting somewhere in that three-way system rather than supplying GH itself — which is the structural difference between a secretagogue and injected recombinant growth hormone.
CJC-1295 sits on the GHRH side. Binds pituitary GHRH receptors to increase both the amplitude of GH pulses and total GH secretion. The DAC (drug affinity complex) version binds serum albumin, extending the half-life from minutes to about a week. In plain terms, it raises the ceiling: when the pituitary does release GH, it releases more of it, and with the DAC variant that elevated baseline persists for days rather than minutes.
Ipamorelin works through the other pathway. Acts as a ghrelin receptor (GHS-R1a) agonist on the pituitary, triggering a clean GH pulse. Its selectivity avoids the appetite and cortisol effects seen with older secretagogues like GHRP-6. It supplies a trigger and, like other ghrelin mimetics, reduces somatostatin tone — the brake — for a short window afterwards.
Why the two are paired
The argument for combining them is that they are not redundant. One raises how much the pituitary is able to release, the other determines when it releases and briefly removes the inhibitory signal. In the older secretagogue literature, giving a GHRH agonist together with a GHRP produced a GH response larger than either agent alone, and that finding is the mechanistic basis everyone cites for this stack.
Ipamorelin is chosen as the GHRP partner specifically because it is the selective one. Earlier secretagogues such as GHRP-6 and GHRP-2 raise GH effectively but drag cortisol, prolactin and appetite along with them. Ipamorelin's own profile notes its weakness as a standalone — weakest gh release of the ghrps — usually stacked with cjc-1295 — which is precisely why it is presented as a partner rather than a solo compound.
An important caveat about naming: "CJC-1295" is used loosely. The DAC version has a multi-day half-life and produces a sustained elevation, while what is sold as "CJC-1295 no-DAC" is Modified GRF 1-29 and clears in roughly half an hour. Those are pharmacologically different situations, and vendors frequently blur them.
Side by side
| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Class | GHRH analogue | Ghrelin receptor (GHS-R1a) agonist |
| Structure | 30 amino acid GHRH analogue | Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) |
| Receptor target | Pituitary GHRH receptor | Pituitary and hypothalamic GHS-R1a |
| Half-life | ~30 minutes without DAC; ~6–8 days with DAC | About 2 hours |
| Administration | Subcutaneous injection, typically before bed on an empty stomach | Subcutaneous injection, 1–3 times daily |
| Storage | Refrigerate reconstituted product; protect from light and avoid shaking | Reconstituted vials refrigerated 2–8 °C, stable ~4 weeks |
| Legal status | Not FDA-approved. Prescribed off-label by some clinics; banned in sport. | Not FDA-approved; compounding restrictions apply in the US. Banned in sport. |
| Evidence grade | Moderate | Moderate |
Both carry a "Moderate" evidence grade on this site: each compound has published human pharmacokinetic or GH-response data, but neither has outcome trials in healthy adults for the body-composition and anti-ageing claims made around them. The combination itself has no dedicated trial at all.
What the research does and does not show
What is reasonably well established is the pharmacology. Teichman et al., 2006 — CJC-1295 pharmacokinetics in healthy adults documented a dose-dependent rise in GH and IGF-1 in healthy adults with a sustained duration of action. Raun et al., 1998 — Ipamorelin, the first selective growth hormone secretagogue characterised the selectivity that made the compound interesting in the first place. Both are real findings in real people.
What is not established is the downstream part — the reason most people search for this pairing. There is no randomised controlled trial showing that raising GH pulses with this combination produces measurable muscle gain, fat loss, better skin or slower ageing in healthy adults. Raising a hormone is a biomarker result; changing a body is an outcome, and the second does not follow automatically from the first. Adult GH-deficiency trials are not a substitute either, because those subjects start from a deficit.
The realistic reading: the mechanism is sound, the acute GH data are genuine, and the long-term risk-benefit picture in healthy people is simply unstudied. Sustained GH and IGF-1 elevation is not neutral — insulin sensitivity, fluid retention and the theoretical concern about accelerating undiagnosed malignancy all belong in that conversation.
Reported effects and known downsides
Commonly reported
- Elevated GH and IGF-1 across the dosing window
- Improved sleep depth reported by most users
- Supports lean mass retention and fat oxidation
- Clean GH pulse without hunger spikes
- Better sleep quality and recovery
- Mild fat-loss and body-composition support
Reported side effects
- Water retention
- Tingling or numbness in hands
- Head rush and flushing after injection
- Elevated fasting glucose at higher doses
- Mild headache
- Injection-site redness
- Light-headedness shortly after dosing
Most of the "benefits" column comes from self-report rather than controlled measurement, which is worth holding in mind: improved sleep and recovery are exactly the sort of subjective endpoints that respond strongly to expectation.
Regulatory status
Neither compound is FDA-approved. Not FDA-approved. Prescribed off-label by some clinics; banned in sport. Not FDA-approved; compounding restrictions apply in the US. Banned in sport. Material sold "for research purposes only" carries no guarantee of identity, purity, sterility or the amount stated on the vial, and that uncertainty applies to every claim on this page about what a given dose does.
Common questions
- What is ipamorelin?
- Ipamorelin is a five-amino-acid growth hormone secretagogue that acts on the ghrelin receptor (GHS-R1a) in the pituitary. Its defining feature is selectivity: it triggers a growth-hormone pulse without the appetite, cortisol and prolactin effects associated with older secretagogues such as GHRP-6.
- What does CJC-1295 do?
- CJC-1295 is an analogue of growth-hormone-releasing hormone. It binds pituitary GHRH receptors and raises the amplitude of natural GH pulses rather than replacing GH itself. The DAC version binds serum albumin, which stretches its half-life from minutes to roughly a week.
- Why are CJC-1295 and ipamorelin combined?
- The two act on different receptors. A GHRH analogue raises the pituitary's willingness to release GH, while a ghrelin-receptor agonist supplies the trigger and blunts somatostatin, the brake on release. In the wider secretagogue literature, combining a GHRH agonist with a GHRP produces a larger GH response than either class alone. That mechanistic rationale — not a trial of this specific branded pairing — is what the combination rests on.
- Are CJC-1295 and ipamorelin FDA approved?
- No. Neither compound is approved by the FDA for any indication. Both are typically sold for research use, both are prohibited in tested sport under WADA rules, and ipamorelin in particular faces US compounding restrictions.
- How are these peptides reconstituted?
- Both arrive as a lyophilised powder that is dissolved in bacteriostatic water before use. The arithmetic of concentration and syringe units is the same for any peptide; the reconstitution calculator on this site works through it, and the bacteriostatic water guide explains what the diluent is.
What this page will not tell you
It gives no dosing schedule, no cycle length, no injection timing and no vendor. Those decisions require a medical history this site cannot see, and both compounds sit outside approved medical use. Read the full disclaimer before acting on anything here, and speak to a clinician who can review your own situation.